These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 23512315)

  • 1. Obesity and hypertension: It's about more than the numbers.
    Ferdinand KC
    Obesity (Silver Spring); 2013 Apr; 21(4):657-8. PubMed ID: 23512315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic syndrome: treatment of hypertensive patients.
    Israili ZH; Lyoussi B; Hernández-Hernández R; Velasco M
    Am J Ther; 2007; 14(4):386-402. PubMed ID: 17667215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chlorthalidone better than hydrochlorothiazide in hypertension].
    Kooter AJ; Smulders YM
    Ned Tijdschr Geneeskd; 2010; 154():A1608. PubMed ID: 20456766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Why chlorthalidone, the thiazide antihypertensive of choice, is neglected?].
    Rumboldt Z
    Lijec Vjesn; 2011; 133(11-12):408-10. PubMed ID: 22329298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis of dose-response characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium.
    Ernst ME; Carter BL; Zheng S; Grimm RH
    Am J Hypertens; 2010 Apr; 23(4):440-6. PubMed ID: 20111008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Black HR; Davis B; Barzilay J; Nwachuku C; Baimbridge C; Marginean H; Wright JT; Basile J; Wong ND; Whelton P; Dart RA; Thadani U;
    Diabetes Care; 2008 Feb; 31(2):353-60. PubMed ID: 18000186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Recent intervention studies with antihypertensive drugs and their influence on guidelines].
    Rahn KH
    Med Klin (Munich); 2003 Dec; 98(12):771-5. PubMed ID: 14685679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapy of hypertension in patients with type 2 diabetes mellitus].
    Hess K
    Dtsch Med Wochenschr; 2012 Nov; 137(48):2489-92. PubMed ID: 23114910
    [No Abstract]   [Full Text] [Related]  

  • 9. Chlorthalidone: the forgotten diuretic.
    Kountz DS; Goldman A; Mikhail J; Ezer M
    Postgrad Med; 2012 Jan; 124(1):60-6. PubMed ID: 22314115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension.
    Jordan J; Yumuk V; Schlaich M; Nilsson PM; Zahorska-Markiewicz B; Grassi G; Schmieder RE; Engeli S; Finer N
    J Hypertens; 2012 Jun; 30(6):1047-55. PubMed ID: 22573071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ESH-ESC guidelines for the management of hypertension.
    Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
    Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azilsartan medoxomil/chlorthalidone: a new fixed-dose combination antihypertensive.
    Pierini D; Anderson KV
    Ann Pharmacother; 2013 May; 47(5):694-703. PubMed ID: 23585646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hypertensive patient with metabolic syndrome: would you prescribe a diuretic as the initial treatment? (interview by Thomas Meissner)].
    Düsing R
    MMW Fortschr Med; 2008 Mar; 150(12):17. PubMed ID: 18533590
    [No Abstract]   [Full Text] [Related]  

  • 14. The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis?
    Schindler C
    Ther Adv Cardiovasc Dis; 2007 Oct; 1(1):7-26. PubMed ID: 19124392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of metabolic syndrome in children and adolescents.
    Pacifico L; Anania C; Martino F; Poggiogalle E; Chiarelli F; Arca M; Chiesa C
    Nutr Metab Cardiovasc Dis; 2011 Jun; 21(6):455-66. PubMed ID: 21565479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The future of antihypertensive treatment.
    Israili ZH; Hernández-Hernández R; Valasco M
    Am J Ther; 2007; 14(2):121-34. PubMed ID: 17414579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil.
    Bakris GL; Sica D; White WB; Cushman WC; Weber MA; Handley A; Song E; Kupfer S
    Am J Med; 2012 Dec; 125(12):1229.e1-1229.e10. PubMed ID: 22939358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Barzilay JI; Davis BR; Cutler JA; Pressel SL; Whelton PK; Basile J; Margolis KL; Ong ST; Sadler LS; Summerson J;
    Arch Intern Med; 2006 Nov; 166(20):2191-201. PubMed ID: 17101936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chlorthalidone Versus Hydrochlorothiazide: A New Kind of Veterans Affairs Cooperative Study.
    Lederle FA; Cushman WC; Ferguson RE; Brophy MT; Fiore Md LD
    Ann Intern Med; 2016 Nov; 165(9):663-664. PubMed ID: 27538129
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of hypertension in individuals with the cardiometabolic syndrome: role of an angiotensin II receptor blocker, telmisartan.
    Francischetti EA; Celoria BM; Francischetti A; Genelhu VA
    Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):289-303. PubMed ID: 18327991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.